Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
115.25
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
December 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Issues $1 Billion Inaugural Sustainability Bond
December 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Accelerating Global Access
December 13, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
All Hands on Deck Against COVID-19
December 10, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Exposures
COVID-19
Merck Issues $1 Billion Inaugural Sustainability Bond
December 13, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Bonds
Emissions
Intellectual Property
Exposures
COVID-19
Debt Markets
Intellectual Property
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
December 10, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Merck Prices $8.0 Billion Debt Offering
December 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
December 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
December 06, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Supports Hiring Our Heroes Corporate Fellowship Program
December 06, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
December 03, 2021
From
Merck & Co., Inc.
Via
Business Wire
Fighting for Health Equity From Inside the Health Care Industry
December 03, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
December 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Creating a New World in Minecraft for Students to Explore
December 01, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces First-Quarter 2022 Dividend
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma
November 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
November 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Completes Acquisition of Acceleron Pharma Inc.
November 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
November 19, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1
November 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
November 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
November 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting
November 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
We're Training More Diverse Investigators to Help Improve Clinical Trials
November 17, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Seramount Names Merck As One of the 2021 Best Companies for Dads
November 12, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Economy
Exposures
COVID-19
Interest Rates
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event
November 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.